Bioglutide is a research material associated with incretin pathways (GLP-1 receptor), which in laboratory research has been linked to glycemic homeostasis, metabolic stress, appetite-regulatory mechanisms, and gastrointestinal motility.
Contents
10 mg powder in a glass vial (research material)
Concentration (test)
Unspecified
Packaging
Glass bottle with sterile cap
Storage
Store in a dry place, at room temperature, away from light.
Molecular formula
Unspecified
Molecular weight
Unspecified
Other names
Bioglutide (incretin/GLP-1 approach – unspecified)
In laboratory studies, Bioglutide is associated with research in areas such as:
- incretin signaling (GLP-1R) and glycemic homeostasis,
- appetite and energy balance in metabolic models,
- gastrointestinal motility and gastric emptying,
- cardiometabolic markers and inflammatory mediators,
- stress pathways and cellular response to nutritional stress.
This content is for educational purposes only. It is not a recommendation for human use. The substance is intended for laboratory research only.
What is Bioglutide?
Bioglutide is a brand name for a research material related to incretin mechanisms, with an emphasis on GLP-1 receptor pathways. In experimental systems, the effect on glycemic balance parameters, signaling cascades and related metabolic indicators is being investigated.
How Bioglutide works
In model conditions, GLP-1R activation and subsequent modulation of cAMP/PKA pathways and other downstream mechanisms that may influence insulin secretion, appetite-regulatory axes, and gastrointestinal transit time are monitored. Effects on inflammatory mediators and cardiometabolic markers are also evaluated.
Researched effects and interesting facts
-
GLP-1 signaling: cAMP-related parameters and beta-cell models.
-
Metabolic balance: Observations on appetite and energy intake.
-
Gastrointestinal motility: Evidence of delayed gastric emptying in models.
-
Cardiometabolic markers: Monitoring lipid and inflammatory markers.
-
Stress pathways: Changes in signals related to nutritional stress.
Dosage in studies
The values listed are derived solely from research studies and are not intended for real-world use outside of a laboratory environment.
-
Dose: Not specified (µg–mg/kg/day are given depending on the model and study objective)
-
Form: injectable after reconstitution (preferred sc or im)
-
Frequency: usually 1x daily to 1x weekly depending on the protocol
-
Duration: generally several weeks in metabolic models
The dosage information is a summary of experimental data and does not constitute instructions for use or a recommendation.
Possible side effects
- Gastrointestinal manifestations in models (nausea, feeling of fullness)
- Changes in appetite and energy intake
- Potential cardiometabolic fluctuations according to protocol
Resources
- Review papers on GLP-1 receptor signaling
- Experimental protocols targeting glycemic homeostasis and GIT motility
- Publications on incretin mechanisms and metabolic models
- Methods for quantifying cardiometabolic markers in the preclinical setting
This article is for informational purposes only. It does not constitute a recommendation or solicitation for use. The information provided is a summary of existing scientific literature and is for educational purposes only.
Sale
